Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 6, 2025 • 10:31 PM ET

Date/Time Source News Release
06/05/2025 08:15 AM EDT Business Wire Saundra Pelletier, Evofem Biosciences' CEO, Dr. Friedrich Kapp, Co-CEO of Adimune, and Chris Mitton, President of Pearsanta, Will Join Aditxt Weekly Update on June 6
05/19/2025 08:00 AM EDT GlobeNewswire Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.
05/19/2025 08:00 AM EDT Business Wire Aditxt Announces Termination of Arrangement Agreement With Appili Therapeutics
05/02/2025 09:00 AM EDT Business Wire Upcoming Aditxt Weekly Update to Feature Dr. Shahrokh Shabahang, Chief Innovation Officer (CIO) of Aditxt(TM), and Dr. Friedrich Kapp, Co-CEO of Adimune(TM), to Discuss Progress of Lead Therapeutic Candidate ADI-100(TM)
04/17/2025 09:08 PM EDT Business Wire KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
04/17/2025 09:03 PM EDT Business Wire KILL Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune(TM)
04/17/2025 08:15 AM EDT Business Wire Dr. Charles Howe of the Mayo Clinic's Neuroimmunology Department to Join Aditxt Weekly Update on May 2, 2025, to Discuss Newly Announced Preclinical Study Results Sponsored by Aditxt's Subsidiary Adimune(TM)
04/16/2025 08:15 AM EDT Business Wire Aditxt Subsidiary Pearsanta Receives IRB Approval to Initiate Clinical Study of Blood-Based Diagnostic for Endometriosis with Patient Enrollment Planned to Begin in May 2025
04/14/2025 08:15 AM EDT Business Wire Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials
04/11/2025 08:15 AM EDT Business Wire Aditxt Weekly Update to Highlight Recent Events, Including Regaining Compliance with Nasdaq Listing Requirements
Page

Additional News

As of June 6, 2025 • 10:31 PM ET

Date/Time Source News Release
05/19/2025 09:57 AM EDT SeekingAlpha Aditxt to terminate arrangement agreement with Appili Therapeutics
05/19/2025 09:15 AM EDT BioMedWire BioMedNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Terminates Acquisition Agreement with Appili Therapeutics 
05/17/2025 05:31 AM EDT US Earnings Reports Expected earnings - Aditxt Inc.
05/02/2025 09:40 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Highlights ADI-100 Developments in Weekly Update Featuring Leadership Team
04/17/2025 10:15 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) to Host Mayo Clinic's Dr. Charles Howe in May 2 Update on ADI-100(TM) Preclinical Study
04/16/2025 09:15 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Gains IRB Approval for Endometriosis Diagnostic Study
04/14/2025 09:35 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Advances Autoimmune Therapy Following Positive Mayo Clinic Study on ADI-100
04/11/2025 08:45 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance and Previews Strategic Updates
04/09/2025 09:35 AM EDT InvestorBrandNetwork InvestorNewsBreaks - Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance, Hearing Canceled
04/09/2025 08:44 AM EDT SeekingAlpha Aditxt regains compliance with Nasdaq
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.